Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease - Ozguroglu, M; Chowdhury, S; Bjartell, A (J Clin Oncol, 2020)
et al.